Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy
Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in heavily pretreated patients with hematological malignancies. However, relapses occur and they limit the efficacy of this promising treatment approach. The cellular composition and immunophenotype of the administ...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 December 2019
|
| In: |
International journal of molecular sciences
Year: 2019, Jahrgang: 20, Heft: 24 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms20246223 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.3390/ijms20246223 Verlag: https://www.mdpi.com/1422-0067/20/24/6223 
|
| Verfasserangaben: | Sophia Stock, Michael Schmitt and Leopold Sellner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1690159073 | ||
| 003 | DE-627 | ||
| 005 | 20220817232417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200217s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms20246223 |2 doi | |
| 035 | |a (DE-627)1690159073 | ||
| 035 | |a (DE-599)KXP1690159073 | ||
| 035 | |a (OCoLC)1341305410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Stock, Sophia |e VerfasserIn |0 (DE-588)1191523071 |0 (DE-627)1670143910 |4 aut | |
| 245 | 1 | 0 | |a Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy |c Sophia Stock, Michael Schmitt and Leopold Sellner |
| 264 | 1 | |c 10 December 2019 | |
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.02.2020 | ||
| 520 | |a Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in heavily pretreated patients with hematological malignancies. However, relapses occur and they limit the efficacy of this promising treatment approach. The cellular composition and immunophenotype of the administered CART cells play a crucial role for therapeutic success. Less differentiated CART cells are associated with improved expansion, long-term in vivo persistence, and prolonged anti-tumor control. Furthermore, the ratio between CD4+ and CD8+ T cells has an effect on the anti-tumor activity of CART cells. The composition of the final cell product is not only influenced by the CART cell construct, but also by the culturing conditions during ex vivo T cell expansion. This includes different T cell activation strategies, cytokine supplementation, and specific pathway inhibition for the differentiation blockade. The optimal production process is not yet defined. In this review, we will discuss the use of different CART cell production strategies and the molecular background for the generation of improved CART cells in detail. | ||
| 650 | 4 | |a adoptive cell therapy | |
| 650 | 4 | |a CAR | |
| 650 | 4 | |a CART | |
| 650 | 4 | |a CART cell production | |
| 650 | 4 | |a chimeric antigen receptor | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a T cell activation | |
| 650 | 4 | |a T lymphocyte | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Sellner, Leopold |d 1984- |e VerfasserIn |0 (DE-588)143493825 |0 (DE-627)646576704 |0 (DE-576)337362963 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d Basel : Molecular Diversity Preservation International, 2000 |g 20(2019,24) Artikel-Nummer 6223, 21 Seiten |h Online-Ressource |w (DE-627)316340715 |w (DE-600)2019364-6 |w (DE-576)281194653 |x 1422-0067 |7 nnas |a Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g number:24 |g extent:21 |a Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms20246223 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/20/24/6223 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200217 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 143493825 |a Sellner, Leopold |m 143493825:Sellner, Leopold |p 3 |y j | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1191523071 |a Stock, Sophia |m 1191523071:Stock, Sophia |d 50000 |e 50000PS1191523071 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1690159073 |e 3596028566 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy","title_sort":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy"}],"note":["Gesehen am 17.02.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"note":["Gesehen am 17.09.20"],"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}],"disp":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapyInternational journal of molecular sciences","part":{"volume":"20","text":"20(2019,24) Artikel-Nummer 6223, 21 Seiten","issue":"24","extent":"21","year":"2019"},"pubHistory":["1.2000 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["1422-0067","1661-6596"],"zdb":["2019364-6"],"eki":["316340715"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"Molecular Diversity Preservation International","dateIssuedKey":"2000","dateIssuedDisp":"2000-","publisherPlace":"Basel"}],"titleAlt":[{"title":"IJMS"}],"recId":"316340715"}],"person":[{"given":"Sophia","role":"aut","roleDisplay":"VerfasserIn","display":"Stock, Sophia","family":"Stock"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Michael","family":"Schmitt","display":"Schmitt, Michael"},{"family":"Sellner","display":"Sellner, Leopold","role":"aut","roleDisplay":"VerfasserIn","given":"Leopold"}],"name":{"displayForm":["Sophia Stock, Michael Schmitt and Leopold Sellner"]},"recId":"1690159073","origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"10 December 2019"}],"language":["eng"],"id":{"doi":["10.3390/ijms20246223"],"eki":["1690159073"]},"physDesc":[{"extent":"21 S."}]} | ||
| SRT | |a STOCKSOPHIOPTIMIZING1020 | ||